ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHU..SK....................................*JBDM Ver 0.1.63 (23 May 2017) - 2999001/020110104201709270201201709272017110620171107201711071504035CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120180228W174deBibliographieenBibliographyfrBibliographieEP03718974.3200305022004120120060116enenen021012120020502GB20180228201809200502092005062010033120101320091009B32017122020175120180228201809C07K 16/28 20060101AFI20031118BHEP C12N 15/13 20060101ALI20031118BHEP C12N 15/85 20060101ALI20031118BHEP C12N 5/10 20060101ALI20031118BHEP A61K 39/395 20060101ALI20031118BHEP A61K 31/7088 20060101ALI20031118BHEP A61P 35/00 20060101ALI20031118BHEP deANTIKÖRPER GEGEN HUMANES CD22 UND DEREN THERAPEUTISCHE UND DIAGNOSTISCHE VERWENDUNGENenANTIBODIES SPECIFIC FOR HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USESfrANTICORPS SPECIFIQUES A L' HUMAIN CD22 ET LEURS UTILISATION THERAPEUTIQUES ET DIAGNOSTIQUESWO-A-00/31141WO-A-00/74718WO-A-01/94585WO-A-91/09967WO-A-92/15683WO-A-94/29451WO-A-96/04925WO-A-98/19704US-A- 5 714 350S. LEUNG ET AL.: "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2." MOLECULAR IMMUNOLOGY, vol. 32, no. 17/18, December 1995 (1995-12), pages 1413-1427, XP000942678 Oxford, GBS. LEUNG ET AL.: "Effect of Vk framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site." INTERNATIONAL JOURNAL OF CANCER, vol. 60, 1995, pages 534-538, XP002066554 New York, NY, USAI. BENHAR ET AL.: "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization." BIOCONJUGATE CHEMISTRY, vol. 5, July 1994 (1994-07), pages 321-326, XP000564453 Washington, DC, USAT. VAUGHAN ET AL.: "Human antibodies by design." NATURE BIOTECHNOLOGY, vol. 16, June 1998 (1998-06), pages 535-539, XP000941675 New York, NY, USA cited in the applicationJ. CARNAHAN ET AL.: "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties." CLINICAL CANCER RESEARCH, vol. 9, no. suppl., 1 September 2003 (2003-09-01), pages 3982S-3990S,J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22." CANCER IMMUNOLOGY & IMMUNOTHERAPY, vol. 54, 2005, pages 11-24,J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies." BLOOD, vol. 103, no. 5, 1 March 2004 (2004-03-01), pages 1807-1814,S. VAN ROSSENBERG ET AL.: "A structure-function study of ligand recognition by CD22beta." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 16, 20 April 2001 (2001-04-20), pages 12967-12973, U.S.A.J. BROWNING: "B cells move to centre stage: Novel opportunities for autoimmune disease treatment." NATURE REVIEWS DRUG DISCOVERY, vol. 5, no. 7, July 2006 (2006-07), pages 564-576,POPPLEWELL, Andrew GeorgeCelltech R & D Limited, 208 Bath RoadSlough, Berkshire SL1 3WEGBTICKLE, Simon PeterCelltech R & D Limited, 208 Bath RoadSlough, Berkshire SL1 3WEGBLADYMAN, Heather MargaretCelltech R & D Limited, 208 Bath RoadSlough, Berkshire SL1 3WEGBUCB Pharma, S.A.100953863P030498EP:CPMAllée de La Recherche 601070 BrusselsBEMercer, Christopher Paulet al100022025Carpmaels & Ransford LLP One Southampton RowLondon WC1B 5HAGBATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEITLILUMCNLPTROSESISKTRAL20041201LT20041201LV20041201MK20041201GB200300193420030502enWO200309332020031113200346